About this trial
Spine SABR is a Phase I/II, multi-centre, non-randomised trial. This study will look at treatment for patients that have already been diagnosed with cancer, but develop a new tumor(s) in the spine. Patients who are not recommended for surgery are usually treated with 5-10 sessions of radiotherapy to manage symptoms. For patients with a longer life expectancy (>6 months), it is better to give a higher dose of treatment to potentially improve the duration of pain relief, cancer control and potentially survival. Higher doses of radiotherapy, however, may also cause worse toxicity and side effects. This study will look at delivering higher doses of radiation in 2 sessions rather than 5-10, using a more modern, targeted technique called image-guided Stereotactic Ablative Body Radiotherapy (SABR).
This study has been designed to determine the maximum tolerated dose of stereotactic radiotherapy, to the spine, delivered in two fractions with a simultaneous integrated boost technique, for patients with oligometastatic or oligoprogressive spine disease. There will be two parallel treatment arms (high versus low baseline risk of post-SABR VCF), and three dose levels of sequential escalation within each arm.
These results will help create national and international guidelines to benefit all cancer patients. It is anticipated that this study will support the delivery of high quality SABR to all cancer patients in Ireland, resulting in potentially better quality of life, symptom and tumor control
The target population for this study are patients with oligometastatic disease (OMD) or oligoprogressive disease (OPD) solid tumour spine metastases.
Where’s this trial being run?
St Luke’s Radiation Oncology Network @ Beaumont Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases
|Principal Investigator:||Prof Clare Faul (Chief Investigator)|
Cancer Trials Ireland
Ireland: November 2023
|Global Recruitment Target:|
|Ireland Recruitment Target:||126|